Orgenesis

Orgenesis operates a decentralized manufacturing and commercialization platform for personalized cell and gene therapies. Under the POCare Platform, the company sources early-stage therapy assets, packages them with proprietary automated processing technology housed in mobile units called OMPULs, and connects to a network of hospitals and research institutions. The goal is to shorten the time and cut the cost required to bring CGTs to market by manufacturing them at or near the point of care rather than at a distant, centralized facility.

The Orgenesis Mobile Processing Unit and Lab — OMPUL — is the physical deployment mechanism for the POCare Platform. It is a contained, GMP-compliant processing environment that can be transported and set up at a local hospital or regional center. By standardizing processing inside identical OMPUL units, Orgenesis claims it reduces facility implementation time from 18–24 months to 3–6 months and creates a harmonized quality framework that can scale across the network.

Orgenesis is a publicly traded biotech operating company, not a family office. It designs and commercializes an infrastructure platform for cell and gene therapies. The firm does not manage a balance sheet of external capital or deploy funds in the style of a family office or asset manager; its model is built on technology licensing, therapy partnerships, and network fees derived from the POCare Platform.

The company identifies early-stage biotechnology developers and partners with academic research institutes and hospitals. Under the POCare Therapies component, Orgenesis brings development and validation of selected assets in-house. The POCare Technologies arm then works with third-party technology providers to build the automated processing systems that are validated for use inside the OMPUL units and across the network.

POCare Centers serve as the regional manufacturing and service hubs within the network. OMPUL mobile units are deployed inside or adjacent to these centers and to local hospitals. The center manages quality assurance, data, and supply chain across the connected OMPULs, enabling a distributed but centrally harmonized manufacturing footprint. As demand grows, additional OMPULs can be linked to the same center.